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One of the most important aspects of quality assurance (QA) in radiation therapy 
is redundancy of patient treatment dose calculation. This work is focused on the 
patient-specific time and 3D dose treatment plan verification for stereotactic radio-
surgery using Leksell Gamma Knife Perfexion (LGK PFX). The virtual model 
of LGK PFX was developed in MATLAB, based on the physical dimensions 
provided by the manufacturer. The ring-specific linear attenuation coefficients 
(LAC) and output factors (OFs) reported by the manufacturer were replaced by the 
measurement-based collimator size-specific OFs and a single LAC = 0.0065 mm-1. 
Calculation depths for each LGK PFX shot were obtained by ray-tracing technique, 
and the dose calculation formalism was similar to the one used by GammaPlan 
treatment planning software versions 8 and 9. The architecture of the QA process 
was based on the in-house online database search of the LGK PFX database search 
for plan-specific information. A series of QA phantom plans was examined to 
verify geometric and dosimetric accuracy of the software. The accuracy of the QA 
process was further evaluated through evaluation of a series of patient plans. The 
shot time/focus point dose verification for each shot took less than 1 sec/shot with 
full 3D isodose verification taking about 30 sec/shot on a desktop PC. GammaPlan 
database access time took less than 0.05 sec. The geometric accuracy (location of 
the point of maximum dose) of the phantom and patient plan was dependent on 
the resolution of the original dose matrix and was of the order of 1 dose element. 
Dosimetric accuracy of the independently calculated phantom and patient point 
(focus) doses was within 3.5% from the GammaPlan, with the mean = 2.3% and 
SD = 1.1%. The process for independent pretreatment patient-specific Gamma 
Knife Perfexion time and dose verification was created and validated. 
PACS numbers: 87.53.Bn; 87.55.-x; 87.56.Bg
Key words: QA, Gamma Knife Perfexion, dose calculation, GammaPlan, ray 
tracing
 
I. IntroDuctIon
Leksell Gamma Knife (Elekta Instruments AB, Stockholm, Sweden) stereotactic radiosurgery 
(SRS) treatments are widely prescribed for a variety of benign and malignant brain abnormali-
ties. Leksell Gamma Knife (LGK) is a major treatment modality for single and multiple brain 
metastases, arteriovenous malformations, and trigeminal neuralgia. Given the fact that most of 
the LGK treatments are single-dose SRS, independent dose calculations are needed to reduce 
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likelihood of serious errors. Commercial solution for independent dose calculation was not 
available for the Gamma Knife Perfexion (LGK PFX) introduced in 2007 and its GammaPlan 
treatment planning software versions 8 and 9 that were installed at  our institution in 2008. The 
importance of independent verification of GammaKnife treatments has been described in recent 
publications,(1,2) which concentrated the quality assurance process of the source configuration 
and point dose verification. This work presents the irradiation time and 3D dose independent 
verification technique. The process can be fully incorporated into the treatment workflow to 
ensure accuracy of patient treatments.
The LGK PFX has a series of significant hardware differences compared to its LGK 
 predecessors. Relevant to this discussion is that the LGK PFX has 192 Co-60 sources, 
arranged in eight sectors (polar angle incremented) and five rings (increment along the patient 
superior–inferior (SI) axis). An LGK PFX sector can be either in open or blocked state. The 
24 sources in each sector are designed to independently slide in the SI direction along the 
‘cone-shaped’ shielded surface of the tungsten collimator to align with apertures that project 
16, 4, and 8 mm diameter beams at the unit center point or ‘beam focus’. The more detailed 
information on the geometry of the new version of the Gamma Knife can be found in multiple 
publications.(1-3) As in the previous versions of Gamma Knife, highly conformal dose distribu-
tions can be generated by a combination of beam apertures, treatment times, head angle, and 
patient shifts relative to the system isocenter. Patient irradiation at each individual treatment 
position is called a “shot”. 
 
II. MAtErIALS AnD MEtHoDS
The virtual model of LGK PFX was built using MATLAB (MathWorks Inc., Natick, MA) 
programming environment, based on the physical dimensions of the machine supplied by the 
manufacturer. After a series of phantom studies, a measurement-based collimator size-specific 
OFs(4) were employed. Output factors were 1, 0.92, and 0.81 for 16, 8, and 4 mm collimator 
sizes, respectively; and a single LAC = 0.0065/mm.
The patient skull surface was reconstructed based on the standard set of Leksell skull scaler 
measurements. In order to obtain the tissue depths for each LGK PFX beam, a simple ray-tracing 
routine that picks a parallel ray to each source-to-focus beam axis (Fig. 1(a)) was used. 
The dose calculation formalism was similar to the one used by GammaPlan treatment plan-
ning software(3) (Fig. 1(b)) for the geometry corresponding to the Eq. (1):
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i
 is the dose rate at the location P resulting from the ith source, 
16,ncalibratiodt
dD
is the current calibration dose rate, which is further normalized to the number of machine 
sources (192), and the subscript index indicates the 16 mm collimator size used in calibration 
setup. The output factor cOF  of the ith source is collimator size-specific, as described earlier. 
The attenuation is accounted for as the factor  )( ncalibratiof Rdde , where d is the depth of the focus 
point measured along the ith beam axis, df is the signed difference between the focus depth and 
the depth of the point P projected onto the ith beam axis, and Rcalibration is the depth of the focus 
point in the calibration geometry (80 mm). The inverse square effect is taken into account by
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the factor 
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d
, where ivSFD   is the collimator size and ring-specific virtual source-to-focus
distance adopted from the manufacturer-provided information.(3) The off-axis beam profile (off-
axis ratio, or OAR), pertinent to the ith source, was scaled according to the beam divergence 
as follows: iff SSDdOADOAR /1/ , where OADf is the off-axis distance at the depth d of 
the focus point, and SSDi is the source-to-surface distance corresponding to the ith source and 
calculated as the difference between ivSFD  and the depth of the point P projected onto the ith 
beam axis. 
The general scheme of the clinical workflow with the incorporated verification process is 
shown in Fig. 2(a). The graphical user interface of the GammaPlan verification tool (GPVT) 
was developed in-house using MATLAB programming environment. Once the treatment plan 
is completed in GammaPlan, it is approved and sent to the machine for treatment. At this time, 
the operator launches the GPVT program to retrieve treatment-related information such as 
 location and number of the targets and shots, and patient skull coordinates from the PostgreSQL 
database that backbones the Leksell GammaPlan treatment planning system. A connection was 
established between the GPVT program and the database via a PostgreSQL Java Database 
Fig. 1. Ray-tracing in case of gamma angle 70° (a) (cyan dots: points of beam surface entry); dose calculation geometry 
(b): Rs, gR, and Rp are radius vectors of an arbitrary Co-60 source, the beam entry point along the skull surface and the 
arbitrary calculation point P, respectively. OAD is the effective off-axis distance used for the off-axis beam profile scaling. 
The angle α between the beam axis and the source-to-point P line is shown. 
(a)
(b)
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Fig. 2. Workflow (a) of the Gamma Knife patient information; steps (b) of the plan verification process. 
(a)
(b)
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Connectivity (JDBC) driver obtained from PostgreSQL’s official website (www.postgresql.
org). Five tables: ‘patients’, ‘examinations’, ‘skulls’, ‘targets’, and ‘shots’ were cross-linked to 
fetch the delivered treatment parameters by specifying the patient’s name and ID. This process 
is shown in Fig. 2(b). The operator selects the examination and current plan used for treatment 
in case multiple plans exist for the patient. The program performs the calculation based on the 
algorithm explained above and outputs the result in an HTML format. The GPVT program has 
been developed in such a way that the PDF treatment plan that is printed out by GammaPlan 
can be parsed, and the results from the GPVT program are compared against their counterpart 
from GammaPlan.
The calculations were performed using the following hardware: Dell Precision T5500, Intel 
Xeon CPU, E5520 @ 2.27 GHz 2.26 GHz, 12 GB RAM. 
A series of QA phantom plans was examined to verify geometric and dosimetric accuracy 
of our software. This was followed by calculation of a series of patient plans, which aimed 
at establishing action criteria for our QA process. We focused on making sure that our GPVT 
software works through a comprehensive set of spherical phantom and patient clinical plans 
(see Table 1 for representative subset of the patient population and diagnoses treated at our 
facility). It was important to show consistent agreement with the GammaPlan focus dose output 
within the accepted clinical tolerance (± 3%) and action (± 5%) limits. The goal was to ensure 
that the extremes caused either by treatment planning software malfunction or operator error 
are filtered out. 
 
III. rESuLtS 
As mentioned in the previous section, Table 1 shows the representative subset of the clinical 
use of the GPVT software in our Gamma Knife Center.
The shot time and focus point dose verification took less than 1 sec per shot, with the full 
3D isodose verification taking about 30 sec per shot. GammaPlan database access time was 
less than 0.05 sec. The geometric accuracy (i.e., location of the point of maximum dose) of the 
phantom and patient plan was dependant on the resolution of the original dose matrix and was 
of the order of 1–1.5 times the dose matrix voxel (“dosel”). During the initial evaluation stage, 
the dosimetric accuracy of independently calculated phantom and patient point dose was within 
3%–3.5%, compared to GammaPlan version 8.3.1, with the mean = 2.3% and SD = 1.1%. 
The graphical user interface of the GPVT software and an example report of independent 
dose calculation for a sample clinical case are demonstrated in Figs. 3(a) and 3(b). The statistics 
of the clinical patient pretreatment focus dose verification is presented in Table 2 for 15 patient 
Table 1. Representative summary of the clinical use of the GPVT. 
 Patient # Diagnosis Number of Shots Time (sec)
 Patient 1 Multiple Metastasis 11 20.99
 Patient 1 Multiple Metastasis 1 2.04
 Patient 1 Multiple Metastasis 5 9.59
 Patient 2 Multiple Metastasis 4 7.93
 Patient 2 Multiple Metastasis 3 5.83
 Patient 3 Multiple Metastasis 2 4.02
 Patient 4 Trigeminal Neuralgia 1 2.06
 Patient 5 Other Benign Tumor 19 37.96
 Patient 6 Multiple Metastasis 10 18.84
 Patient 6 Multiple Metastasis 2 4.01
 Patient 7 Acoustic Schwannoma 14 27.73
 Patient 8 Single Metastasis 6 11.26
 Patient 9 Acoustic Schwannoma 12 23.76
 Patient 10 Single Metastasis 9 17.29
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cases: the average calculated-to-planned dose ratio over the planned number of shots, standard 
deviation, and the range of calculated ratios of GPVT to GammaPlan focus dose. All of the 
GPVT calculated average doses to the target deviated from the GammaPlan dose within 3% 
range, with 6 shot doses out of total 203 shots examined being out of ± 5% range.  
Fig. 3. Graphical User Interface (a) of the GammaPlan verification tool (GPVT); HTML report (b) of the results obtained 
from GPVT.
(a)
(b)
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Figures 4 (a) to 4(c) show isodose comparison in axial, sagittal, and coronal planes of the 
two dose matrices: one, calculated by GammaPlan, and the second matrix calculated by our 
LGK PFX QA software. The contour graphs demonstrate the close proximity and similarity 
of shape of 12.5%, 25%, 50%, 75%, and 90% isodose lines. Figure 4(d) shows the example of 
additional dose information printed out for each QA run, which also reveals a reasonably good 
agreement between the independently calculated and the GammaPlan dose. 
 
Table 2. Statistics of the clinical plan dose verification: average over the number of shots, standard deviation, and the 
range of calculated ratios of GPVT to GammaPlan focus dose.
 GPVT Calculated vs. GammaPlan 
 Patients Number of Shots Average S.D. Max Min
 1 15 0.998 0.008 1.006 0.983
 2 7 1.015 0.005 1.019 1.005
 3 18 1.002 0.008 1.018 0.991
 4 25 1.018 0.018 1.049 0.988
 5 17 0.967 0.013 0.984 0.947
 6 12 0.990 0.009 0.999 0.969
 7 3 0.981 0.003 0.984 0.978
 8 14 1.021 0.019 1.038 0.960
 9 30 0.978 0.014 1.021 0.955
 10 13 0.996 0.004 1.002 0.993
 11 18 1.026 0.012 1.048 1.008
 12 6 0.973 0.003 0.977 0.968
 13 2 0.979 0.003 0.981 0.977
 14 12 0.956 0.010 0.976 0.943
 15 11 0.997 0.008 1.008 0.983
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Fig. 4. Full dose calculation results (patient information omitted): (a)–(c) isodose comparison display for three sample 
clinical plans; (d) sample dose comparison output.  
(a)
(b)
(c)
(d)
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IV. DIScuSSIon
Among likely sources of the 3D dose discrepancies between the GammaPlan and an independent 
dose verification QA software such as GPVT, several can be pointed out: the difference in skull 
surface interpolation between the vendor’s and our MATLAB routine; and necessary interpola-
tions performed in order to combine the multiple shot doses together in a single matrix. The former 
can be eliminated in situations where the vendor software is switched to using the patient CT 
numbers for rendering the skull surface, which could be easily implemented in our QA program. 
As the measurement of the relative output factors presents a continuous challenge,(4-6) building a 
reasonably fast Monte Carlo-based dose calculation engine seems to be the likely solution for the 
comprehensive independent time and dose verification for Gamma Knife treatment.(7,8) Unlike the 
simple ray-tracing–based technique presented in this work, the Monte Carlo approach would be 
able to take into account the leakage and scatter contribution into the total delivered dose, which 
can have a noticeable effect in case of the smallest 4 mm collimator size, due to the lowest output.
(1,7) However, as a fast pretreatment verification of the patient treatment parameters, our QA routine 
ensures that focus dose is within the accepted clinical tolerance and/or action (± 5%) limits, and the 
extreme cases of treatment planning software malfunction or operator error are red flagged.  
Comparing the presented dose verification method to that used by Wright et al.(2) shows that 
incorporating the interpolated skull surface model that is based on the skull scaler helmet mea-
surements delivers similar results to the point dose calculations. 
 
V. concLuSIonS
An automated method of the patient-specific treatment plan quality assurance for Leksell Gamma 
Knife Perfexion stereotactic radiosurgery is presented. The technique employs fast database access 
for the remote read-only extraction of treatment specifications from the GammaPlan PFX patient 
SQL database over the local network. It enables independent treatment plan verification on a 
separate PC workstation so that the FDA approval of GammaPlan software is not compromised. 
The software independently computes and compares with the GammaPlan dose rates at selected 
points of interest, and computes and displays isodose distribution and the time for each shot for 
comparison with the GammaPlan results. 
The LGK PFX QA code was validated using phantom and  anonymous patient plans with 
clinically relevant agreement with the GammaPlan TPS version 8.3.1. The code workflow is 
tested to be fast and suitable for the pretreatment plan verification. 
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